Forte Biosciences (FBRX) Gains from Investment Securities (2016 - 2026)
Forte Biosciences (FBRX) reported Gains from Investment Securities of $75000.0 for Q1 2026, down 96.77% year-over-year from $2.3 million in Q1 2025, and up 1150.0% quarter-over-quarter from $6000.0 in Q4 2025.
Forte Biosciences (FBRX) Gains from Investment Securities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Gains from Investment Securities data on file, last reported at $75000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $75000.0, down 96.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $75000.0 (down 96.77% YoY), and the FY2025 annual result was $2.6 million, up 1132.98% from the prior year.
- Gains from Investment Securities grew to $75000.0 in Q1 2026 per FBRX's latest filing, from $6000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.6 million in Q3 2023 and troughed at $6000.0 in Q4 2025.
- A 5-year average of $1.0 million and a median of $212501.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities surged 2576.35% in 2023, then tumbled 97.18% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $2.4 million in 2022, then slumped by 95.52% to $105791.0 in 2023, then jumped by 100.87% to $212501.0 in 2024, then plunged by 97.18% to $6000.0 in 2025, then surged by 1150.0% to $75000.0 in 2026.
- Business Quant data shows FBRX's Gains from Investment Securities at $75000.0 in Q1 2026, $6000.0 in Q4 2025, and $93598.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75,000.00 |
| Mar 31, 2026 | 75,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 93,598.00 |
| Sep 30, 2025 | 93,598.00 |
| Jun 30, 2025 | 10,705.00 |
| Jun 30, 2025 | 10,705.00 |
| Mar 31, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 212,501.00 |
| Dec 31, 2024 | 212,501.00 |
| Sep 30, 2024 | 123,600.00 |
| Sep 30, 2024 | 123,600.00 |
| Jun 30, 2024 | 372,353.00 |
| Jun 30, 2024 | 372,353.00 |
| Mar 31, 2024 | 2.54 Mn |
| Mar 31, 2024 | 2.54 Mn |
| Dec 31, 2023 | 105,791.00 |
| Dec 31, 2023 | 105,791.00 |